NEW YORK (TheStreet) -- CHANGE IN RATINGS:
AFLAC AFL was downgraded at Sterne Agee to neutral from buy. Trading near 52-week highs despite negative EPS revision pressure, Sterne Agee said.
Altera ALTR was downgraded at Lazard Capital Markets from buy to neutral. Company faces macro growth headwinds, Lazard Capital Markets said.
TD Ameritrade AMTD was downgraded at Sterne Agee to neutral. $19 price target. Valuation call, as the stock is up 20% from its November lows, Sterne Agee said.
American Express AXP was downgraded at J.P. Morgan from neutral to underweight. $60 price target. Company may struggle to regain its operating leverage, J.P. Morgan said.
B/E Aerospace BEAV was downgraded at Deutsche from buy to hold. Valuation call, based on a $55 price target, Deutsche said.
Boston Scientific BSX was upgraded at Credit Suisse from neutral to outperform. $7.50 price target. Sales visibility is improving, Credit Suisse said.
Celgene CELG was upgraded at Bank of America/Merrill Lynch from neutral to buy. $115 price target. Company can deliver 25% compound annual earnings growth over the next five years, BofA/Merrill said.
Cliffs Natural CLF was upgraded at Deutsche Bank from hold to buy. $48 price target. Sector is down, despite higher commodity prices, Deutsche said.
Duke Energy DUK was upgraded at UBS to buy from neutral. $70 price target. Attractive risk/reward profile, UBS said.
Consolidated Edison ED was downgraded at UBS to sell from neutral. $53 price target. New York politics leads to regulatory interference, UBS said.
FMC Technologies FTI was upgraded at Morgan Stanley to overweight. $65 price target. Company is leveraged to better subsea processing and services demand, Morgan Stanley said.
Green Mountain GMCR was upgraded at Argus from hold to buy. $50 price target. Company has strong brands and can benefit from higher coffee prices, Argus said.
Global Payments GPN was initiated with a buy rating at UBS. $57 price target. Unique asset with difficult to replicate global footprint, UBS said.
Hyatt Hotels H was initiated with an outperform rating at BMO Capital Markets. $45 price target. Strong growth potential, BMO said.
US Airways LCC was downgraded at J.P. Morgan to neutral. See limited upside potential, even with an expected UAL merger, J.P. Morgan said.
Marriott International MAR was initiated at BMO Capital Markets with a market perform rating. $41 price target. North America is not a bad place to be, BMO said.
Nektar Therapeutics NKTR was initiated at Lazard Capital Markets with a buy rating. $15 price target. A bounty of attractive late stage programs, Lazard Capital Markets said.
Pharmacyclics PCYC was initiated at Credit Suisse with an outperform rating. $79 price target. Most derisked pure play in oral lymphoma/leukemia drug class, Credit Suisse said.
Patterson PDCO was downgraded at Goldman Sachs from neutral to sell. Company will likely be hurt by lower demand for high-tech dental equipment, Goldman said.
Petrologistics PDH was upgraded at Citigroup to buy from neutral. $17 price target. Elevated propane to propylene spread seems sustainable given warm weather, Citigroup said.
PDL Biopharma PDLI was downgraded at Credit Suisse from neutral to underperform. Valuation call, based on a $6 price target, Credit Suisse said.
Principal Financial Group PFG was downgraded at Sterne Agee to neutral from buy. Valuation call, Sterne Agee said.
Regeneron Pharmaceuticals REGN was downgraded at Jefferies downgraded to hold from buy. Limited upside on Eylea, Jefferies said.
Sirona Dental SIRO was downgraded at Goldman Sachs from buy to neutral. Valuation call, based on a $67 price target, Goldman Sachs said.
Symantec SYMC was upgraded at Morgan Stanley to overweight. $25 price target. Visibility is improving, and the company offers the best risk/reward in the industry, Morgan Stanley said.
United Continental UAL was downgraded at J.P. Morgan to neutral. Valuation call, based on a $30 price target, J.P. Morgan said.
Vantiv VNTV was initiated with a neutral rating at UBS. $22 price target. Attractive secular exposure, but fully valued shares, UBS said.
Vertex Pharmaceuticals VRTX was downgraded at Lazard Capital Markets to neutral. Company is likely facing a transition year, Lazard Capital Markets said.
Watsco WSO was downgraded at Robert Baird from outperform to neutral. Valuation call, based on a $77 price target, Robert Baird said.
STOCK COMMENTS / EPS CHANGES
Apple AAPL estimates, target reduced at Nomura. Shares of AAPL now seen reaching $530. Estimates also cut, given lower expected iPhone sales. Neutral rating.
Caterpillar CAT target raised at Credit Suisse to $124, according to Credit Suisse. Survey suggests that dealers are meeting sales forecasts. Outperform rating.
Dell DELL target raised at Jefferies to $13, Jefferies said. LBO is a possibility. Hold rating.
Rock Tenn RKT cut from Conviction Buy List at Goldman. Valuation call, based on an $83 price target.
St. Jude Medical STJ numbers raised at Jefferies. Shares of STJ now seen reaching $39, Jefferies said. Estimates also raised on ending of near- term pressure from Riata/Durata. Hold rating.
>To submit a news tip, email: firstname.lastname@example.org.
READERS ALSO LIKE: